Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase.
The ability of heparin glycosaminoglycan to prevent formation of the properdin-stabilized amplification C3 convertase is independent of antithrombin binding activity and requires substitution of the amino sugar and a degree of oxygen (O)-sulfation which could be on the uronic acid or the amino sugar. Preparations of heparin glycosaminoglycan isolated by different techniques from different species (rat, human, and porcine) exhibited an equivalent capacity to inhibit generation of the amplification C3 convertase. Hyaluronic acid, which is devoid of O-sulfation, had no inhibitory activity; chondroitin 4-sulfate of rat and whale origins, chondroitin 6-sulfate of rat and shark origins, and dermatan sulfate from porcine skin are O-sulfated on the galactosamine and had minimal activity. Porcine heparin glycosaminoglycan, isolated on the basis of affinity for antithrombin III, had no greater anticomplementary activity than porcine glycosaminoglycan, which failed to bind antithrombin III and had essentially no anticoagulant activity. Nitrogen (N)-desulfation of porcine heparin reduced anticomplementary activity to the level of the other sulfated mucopolysaccharides, and both N-resulfation and N-acetylation restored the original activities, thereby indicating a requirement for N-substitution, but not N-sulfation. N-resulfation of N-desulfated and O-desulfated heparin did not restore any activity, thus indicating that O-sulfation and N-substitution represent independent, critical structural requirements for the anticomplementary activity of heparin glycosaminoglycan. Inasmuch as N-desulfated-N-acetylated heparin had no anticoagulant activity, the nature of the N-substitution completely distinguishes the plasma-protein effector pathway that is inhibited.
D000107:Acetylation; D000818:Animals; D001777:Blood Coagulation / Q000187:drug effects; D055598:Chemical Phenomena; D002621:Chemistry; D002809:Chondroitin Sulfates / Q000494:pharmacology; D003166:Complement Activating Enzymes / Q000096:biosynthesis*; D050577:Complement C3-C5 Convertases / Q000096:biosynthesis*; D003871:Dermatan Sulfate / Q000494:pharmacology; D006493:Heparin / Q000494:pharmacology*; D006801:Humans; D006820:Hyaluronic Acid / Q000494:pharmacology; D051381:Rats; D013329:Structure-Activity Relationship; D013552:Swine
D003871:Dermatan Sulfate; D006820:Hyaluronic Acid; D006493:Heparin; D002809:Chondroitin Sulfates; D003166:Complement Activating Enzymes; D050577:Complement C3-C5 Convertases